(MedPage Today) — SAN FRANCISCO — Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.
Interim results from the phase II/III ADAPT Jr study showed that efgartigimod (Vyvgart), a drug approved…
Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118275
Author :
Publish date : 2025-11-03 16:22:00
Copyright for syndicated content belongs to the linked Source.
